A Sedation/Cognition/Electroencephalogram (EEG) Study using AZD7325 and Comparator.

Study identifier:D1140C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase 1, single centre, single dose, double-blind, double-dummy, four-way crossover, placebo-controlled, randomized study to investigate the effects of AZD7325 on sedation, cognition and electroencephalogram (EEG) in comparison with lorazepam in healthy male volunteers.

Medical condition

Healthy Volunteer

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7325, Lorazepam

Sex

Male

Actual Enrollment

16

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Jun 2008
Primary Completion Date: 01 Aug 2008
Study Completion Date: 01 Aug 2008

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria